Navigation Links
NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents
Date:5/5/2009

HUBBARD, Ohio, May 5 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets: NNLX) NanoLogix personnel will display the company's BNP(TM) rapid-detection technology at booth 749 during the 109th Annual ASM Meeting to be held at the Pennsylvania Convention Center in Philadelphia May 17th - 21st. The ASM meeting is the world's premier event for microbiology development. Representing NanoLogix will be Dr. Sergey Gazenko and CEO Bret Barnhizer. Exhibition information can be found at http://gm.asm.org/

NanoLogix recently received two patents. United States patent number 7,524,623 was granted for a "Method and device for rapid detection of microorganisms by changing the shape of micro-colonies" and is the first patent granted the company for BNC(TM) rapid-detection technology. Christopher Novak, NanoLogix Director of Intellectual Property said, "The issuance of the first US patent for the BioNanoChannel(TM) (BNC) this past week is a very significant development for NanoLogix. This patent provides NanoLogix with substantial intellectual property protection for their revolutionary rapid-detection technology. This greatly strengthens NanoLogix's patent portfolio with additional patents anticipated in the family of patent applications on file for this technology."

BNP(TM) and BNC(TM) are two distinct micro-biological rapid-detection technologies developed by NanoLogix. The BNP is a sandwiched-membrane, Petri-based system, that provides users the ability to view microorganism cultures up to four times faster than possible with traditional Petri techniques. The BNC is also a unique development in rapid detection. It utilizes disks the size of a quarter, each containing over two-million channels, to trap microorganisms for identification and culturing. Both BNP and BNC technologies offer the potential for reducing time-to-detection by significant amounts when contrasted with current methods in widespread use.

United States patent number 7,473,552 for the "Production of hydrogen gas and isolation of hydrogen producing microorganisms using replenishing coated substrates" was also recently received. The company adds this patent to their existing archived hydrogen-related research portfolio.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.

More information on NanoLogix is available at: www.nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

        Contact:
        NanoLogix, Inc.
        Investor Relations
        Carol Surrena
        Telephone: 330-534-0800
        E-mail: carol@nanologix.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
2. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
3. NanoLogix Inc. to Present at EBW Expo & Conference 2007
4. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
5. NanoLogix, Inc. Makes Stock Pick List
6. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
7. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
8. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
9. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
10. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
11. NanoLogix Inc. Announces Joint Development With CL Solutions and First Sales of Rapid Detection Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Stock-Callers.com explores the Biotech industry to ... recent performances of select equities. In this morning,s lineup ... Abeona Therapeutics Inc. (NASDAQ: ABEO ), Theravance ... Therapeutics Inc. (NASDAQ: SAGE ). According to ... market size is expected to reach $604.40 billion by 2020 due to ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
Breaking Biology Technology:
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
Breaking Biology News(10 mins):